Trial Profile
A randomised phase II trial of Selinexor, cyclophosphamide and prednisone vs cyclophosphamide and prednisone in relapsed or refractory multiple myeloma (RRMM) patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Cyclophosphamide; Prednisolone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK Twelve
- 28 Jun 2021 Planned End Date changed from 1 Apr 2021 to 30 Nov 2022.
- 28 Jun 2021 Status changed from completed to active, no longer recruiting.
- 05 Apr 2021 Status changed from active, no longer recruiting to completed.